SAMe shown to lower liver toxicity in chemotherapy treatment. SAMe could be a powerful chemotherapeutic adjuvant. This makes since, because cancer is known to be a hypomethylated state. Low methyl donors will reduce CBS activity and thus lower glutathione. This will result in increased oxidative stress and inflammation in the liver. SAMe will open the CBS activity up and increase glutathione production.